Market news

--QuidelOrtho Corporation, a global leader in in vitro diagnostics, is proud to share episode 61 of its Science Bytes podcast, highlighting key insights about lowering sepsis rates in the emergency room. Sepsis remains a leading cause of death in the U.S. Barriers to diagnosis lead to organ failure and higher mortality rates. Hosted by Josh Casey, this episode...

Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference.

In early August 2026, QuidelOrtho reported second-quarter 2026 results showing sales of US$630.9 million and a net loss of US$92.9 million, alongside narrower losses per share than a year earlier. However, for the first half of 2026, sales eased to US$1.25 billion and the company reduced its full-year revenue outlook to US$2.52–2.60 billion, highlighting softer expectations despite improving losses. With QuidelOrtho lowering its full-year 2026 revenue guidance, we’ll now examine how this...

Healthcare Equipment and Supplies Stocks Q2 In Review: QuidelOrtho (NASDAQ:QDEL) Vs Peers

QuidelOrtho’s second quarter results were met with a negative market reaction, reflecting investor concern over significant challenges in key markets. While management pointed to solid demand in North America and strong commercial execution in regions like Japan and Latin America, CEO Brian J. Blaser cited a “softer respiratory environment” and pronounced weakness in China as primary factors impacting performance. The company’s leadership was notably cautious, highlighting that China revenue fel

Motley Fool Press Release.

The sharp reset in QuidelOrtho’s fair value estimate from US$20.50 to US$12.00 per share sits alongside analyst price targets that now cluster around the US$12 to US$18 range. Recent research has become more divided, with some firms lifting targets while holding Neutral ratings and others, such as JPMorgan at US$12, keeping a more cautious stance. As you read on, you will see how these shifting targets feed into the broader narrative around risk, execution, and what to watch next with...

QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.

Moby summary of QuidelOrtho Corporation's Q2 2026 earnings call

QuidelOrtho (NASDAQ:QDEL) reported second-quarter revenue growth despite continued pressure from China and a softer respiratory testing environment, while lowering its full-year outlook and withdrawing free cash flow guidance. Total second-quarter revenue was $631 million, up 2% on a constant-curre

Detailed price information for Quidelortho Corp (QDEL-Q) from The Globe and Mail including charting and trades.

Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) announced better-than-expected revenue in Q2 CY2026, with sales up 2.8% year on year to $630.9 million. On the other hand, the company’s full-year revenue guidance of $2.56 billion at the midpoint came in 5.4% below analysts’ estimates. Its non-GAAP profit of $0.13 per share was significantly above analysts’ consensus estimates.

Investors need to pay close attention to QDEL stock based on the movements in the options market lately.

Detailed price information for Quidelortho Corp (QDEL-Q) from The Globe and Mail including charting and trades.

QuidelOrtho (QDEL) To Report Earnings Tomorrow: Here Is What To Expect

QuidelOrtho stock has seen a steep share price decline over the past few years, yet the current valuation checks still lean toward the shares looking inexpensive on several measures. Over the last 5 years, QuidelOrtho shareholders have seen the stock fall about 88.5%, which means today’s price is being set after a long period of weak returns. Future revenue and margin progress can support the current price, while any setbacks in turning that into consistent cash flow remain a key risk for...

QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, announced today that it will report its financial results for the second quarter 2026 ended June 28, 2026, after the market closes on Thursday, August 6, 2026.

QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.

Terumo stands out as medical products companies navigate cost pressures with innovation, pricing actions and demand for advanced diagnostics supporting growth.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at QuidelOrtho (NASDAQ:QDEL) and the best and worst performers in the healthcare equipment and supplies industry.

Detailed price information for Quidelortho Corp (QDEL-Q) from The Globe and Mail including charting and trades.